Company Overview of SanBio, Inc.
SanBio, Inc. develops regenerative therapies for neurological disorders. Its product pipeline includes SB623, which integrates into the tissue and reverses neural damage; SB618 for the treatment of conditions that affect the myelin sheath of neurons, such as multiple sclerosis and spinal cord injury; and SB308, which uses donor bone marrow to create muscle progenitor cells. The company’s products are used for the treatment of various neurological disorders, including stroke, spinal cord injury, Parkinson's disease, and multiple sclerosis. SanBio, Inc. was founded in 2001 and is based in Mountain View, California. SanBio, Inc. operates as a subsidiary of SanBio Company Limited.
231 South Whisman Road
Mountain View, CA 94041-1522
Founded in 2001
Key Executives for SanBio, Inc.
Co-Founder, Chairman and Co- Chief Executive Officer
Co-Founder, Co- Chief Executive Officer and Director
Senior Vice President of Production Development
Chief Medical Officer and Head of Research
Compensation as of Fiscal Year 2015.
SanBio, Inc. Key Developments
Sanbio Inc. Begins Recruiting Patients to Test Regenerative Treatment for Traumatic Brain Injury
Oct 5 15
SanBio Inc. announced that it has opened patient recruitment for its Phase 2 clinical trial study to evaluate the clinical efficacy and safety of its proprietary cell therapy following traumatic brain injury (TBI). In the United States alone, more than 5.3 million people live with disabilities caused by TBI - with approximately 1.5 million people suffering from such an injury each year. The effects can be devastating, often requiring long-term rehabilitation and care to overcome severe neurological deficits, including cognitive and motor-function impairment. The Phase 2 clinical trial follows a Phase 1/2a clinical trial in patients with chronic motor deficit secondary to ischemic stroke, which showed statistically significant improvements in motor function following implantation of SB623 cells. The Phase 2 study will further evaluate the efficacy and safety of the treatment, as well as the safety and tolerability of the administration process. Patients must be between 12-36 months post injury. The study will be conducted across approximately 20 clinical trial sites throughout the United States. Total enrollment is expected to reach 52 patients.
SanBio, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014
Sep 10 14
SanBio, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.
SanBio, Inc. Presents at BIO-Europe 2014, Nov-04-2014 03:00 PM
Sep 3 14
SanBio, Inc. Presents at BIO-Europe 2014, Nov-04-2014 03:00 PM. Venue: Portalhaus Messe Frankfurt, Strasse der Nationen, 60327 Frankfurt, Germany.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|